UNSPSC 41202047: Proteus spp. (weil-felix) serological reagents

In this classification, Proteus genus (weil-felix) serological reagents are devices used in test to identify specific Proteus genus (weil-felix) antibodies in serum. US FDA regulates Proteus genus (weil-felix) serological reagents under 21 CFR 866.3410 and under FDA product code GSZ.

UNSPSC 41202047 Proteus spp. (Weil-Felix) serological reagents (Commodity) shows minimal recent activity aligned with the code's nominal scope. State and local governments procure HIV and Syphilis testing reagents, blood chemistry panels, and forensic serological analysis under related codes much more actively than they do Proteus-specific serology. The recent opportunities in the block overwhelmingly feature HIV testing kits, Syphilis reagents, Hepatitis screening assays, and general clinical diagnostic laboratory services—none of which directly invokes Proteus Weil-Felix serology. When Proteus serology does appear in state and local procurement, it is typically bundled within broader HIV or Syphilis testing platforms (such as fourth-generation combination assays) or forensic serology protocols, rather than procured as a standalone reagent line.

The issuing bodies span state health departments (Illinois Department of Public Health), county corrections and supervision agencies (Collin County Community Supervision and Corrections Department in Texas), municipal health departments (City of Austin Public Health), state criminal justice departments (Texas Department of Criminal Justice), and higher-education institutions (University of Houston). Geographic activity centers on Illinois and Texas, with secondary presence in Florida (Collier County). Representative recent opportunities include the Illinois Department of Public Health's February 2026 Invitation for Bid (IFB) for Hepatitis, HIV, and Syphilis fourth-generation combination screening assays and instrumentation (response due March 16, 2026), Collin County's July 2026 RFP for offender specimen collection and drug testing services with immunoassay and confirmatory testing (response due July 23, 2026, estimated contract value $600,000 over two years with three optional one-year renewals), and the City of Austin's June 2026 Invitation for Bid for rapid HIV Type 1 and Type 2 test kits (response due July 17, 2026). The code does not show sustained or material state and local procurement activity focused on Proteus Weil-Felix serology as a discrete commodity or service.